Drug approvals for new Alzheimer's treatments delayed past 2026-12-31

At least one new Alzheimer's drug pending FDA review in mid-2026 will not receive approval by the end of the year due to leadership uncertainty and policy shifts at the agency.

Implied probability (Yes)

60%